| Literature DB >> 34886838 |
Farzad Mazloomirad1, Sajad Hasanzadeh2, Asghar Sharifi3, Gordafarin Nikbakht4, Narges Roustaei5, Seyed Sajjad Khoramrooz6,7.
Abstract
BACKGROUND: Hospital-acquired pneumonia (HAP) is the second most common nosocomial infection in intensive care units (ICUs). The present study aims to determine the prevalence of pathogenic bacteria, their biofilm formation, and molecular typing from patients with HAP in southwestern Iran.Entities:
Keywords: Acinetobacter baumannii; Biofilms; Hospital-acquired pneumonia; MRSA; Molecular typing
Mesh:
Year: 2021 PMID: 34886838 PMCID: PMC8662843 DOI: 10.1186/s12890-021-01773-3
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
The primers oligonucleotide sequences used in this study
| Target gene | Primer sequence (5′ → 3′) | Amplicon Length, bp | References |
|---|---|---|---|
F-CTG GCA TAT GTA TGG CAA TTG TT R-TAT TGA CCT GAA TCA GCG TTG TCT | 670 | [ | |
F-AAGGTGCGAATGTGACGGTG R-AACTGGTTCTACGTCAGGCA | 620 | [ | |
F-CCC GTT TTA CCC GGA AGA AG R-GGA AAG AAG ATG GCA TCC TGC | 243 | [ | |
F-TTCCGGTGAAGGTGCCAAT R-ACCGGACGCTCTTTACCATA | 507 | Unpublished data | |
F-GACATCAACCACCGCGAAAT R-GGACCCCAAAGAGCAGAGAT | 332 | Unpublished data | |
F-GTG AAG ATA TAC CAA GTG ATT R-ATG CGC TAT AGA TTG AAA GGA T | 147 | [ | |
| SCC | F-GCTTTAAAGAGTGTCGTTACAGG R-GTTCTCTCATAGTATGACGTCC | 613 | [ |
| SCC | F-CGTTGAAGATGATGAAGCG R-CGAAATCAATGGTTAATGGACC | 398 | [ |
| SCC | F-CCATATTGTGTACGATGCG R-CCTTAGTTGTCGTAACAGATCG | 280 | [ |
| SCC | F-GCCTTATTCGAAGAAACCG R-CTACTCTTCTGAAAAGCGTCG | 776 | [ |
| SCC | F-TCTGGAATTACTTCAGCTGC R-AAACAATATTGCTCTCCCTC | 493 | [ |
| SCC | F-ACAATATTTGTATTATCGGAGAGC R-TTGGTATGAGGTATTGCTGG | 200 | [ |
| SCC | F-CTCAAAATACGGACCCCAATACA R-TGCTCCAGTAATTGCTAAAG | 881 | [ |
| SCC | F-GAACATTGTTACTTAAATGAGCG R-TGAAAGTTGTACCCTTGACACC | 325 | [ |
| R-GTCACAAGTACTATAAGCTGCGAT | 440 | [ | |
| R-GTATTACTAATTGAAAAGTGCCATAGC | 573 | [ | |
| R-CTGTTGAAAAAGTCAACTAAAAGCTC | 406 | [ | |
| R-CGATAATGCCGTAATAC CCG | 588 | [ | |
| pan-agr | F-ATGCACATGGTGCACATGC | [ |
Demographic and clinical characteristics of patients with HAP
| Culture positive | Culture negative | |||
|---|---|---|---|---|
| Total (N = 52) | VAP (N = 36) | NV HAP (N = 16) | Total (N = 6) | |
| Female | 27 (51.9%) | 17 (47.2%) | 10 (62.5%) | 2 (33.3%) |
| Male | 25 (48.1%) | 19 (52.8%) | 6 (37.5%) | 4 (66.7%) |
| Average age (YRS) | 57.92 | 59.39 | 54.64 | 62.5 |
| Fever | 43 (82.7%) | 30 (83.3%) | 13 (81.2%) | 5 (83.3%) |
| Sputum | 43 (82.7%) | 30 (83.3%) | 13 (81.2%) | 4 (66.7%) |
| Chest pain | 15 (28.8%) | 9 (25%) | 6 (37.5%) | 2 (33.3%) |
| Cough | 10 (19.2%) | 7 (19.4%) | 3 (18.7%) | 2 (33.3%) |
| Underlying disease | 20 (38.4%) | 14 (38.9%) | 6 (37.5%) | 1 (16.7%) |
Bacterial identified in this study from patients with VAP and NV-HAP using culture and PCR methods
| Bacteria | VAP | NV-HAP | ||||
|---|---|---|---|---|---|---|
| Culture (N = 38) | PCR (N = 39) | Culture (N = 16) | PCR (N = 17) | |||
| 18 (47.4%) | 18 (46.2%) | 2 (12.5%) | 2 (11.8%) | 0.016 | 0.014 | |
| 10 (26.3%) | 10 (25.6%) | 3 (18.7%) | 3 (17.6%) | 0.554 | 0.518 | |
| 6 (15.8%) | 6 (15.4%) | 9 (56.3%) | 9 (52.9%) | 0.003 | 0.004 | |
| 4 (10.5%) | 5 (12.8%) | 2 (12.5%) | 2 (11.8%) | 0.832 | 0.918 | |
| 0 | 0 | 0 | 1 (5.9%) | – | – | |
| Total | 100% | 100% | 100% | 100% | ||
*Between the cultures of the two groups VAP and NV-HAP
**Between the PCR of the two groups VAP and NV-HAP
Biofilm production of bacterial isolates in the present study from patients with HAP
| Microtiter plate method | Congo red agar method | Total | |||
|---|---|---|---|---|---|
| Strong biofilm producer | 18 (90%) | 12 (92.3%) | 3 (50%) | 7 (46.7%) | 40 (74%) |
| Moderate biofilm producer | 2 (10%) | 1 (7.7%) | 1 (16.7%) | 4 (26.7%) | 8 (14.8%) |
| Weak biofilm producer | – | – | 1 (16.7%) | 2 (13.3%) | 3 (5.6%) |
| Negative biofilm | – | – | 1 (16.6%) | 2 (13.3%) | 3 (5.6%) |
The antibiotic resistance patterns of the Gram-positive and Gram-negative bacterial isolates from patients with HAP
| Antibiotics | ||||
|---|---|---|---|---|
| Penicillin | 93% | – | – | – |
| Cefoxitin | 80% | – | – | – |
| Clarithromycin | 73% | – | – | – |
| Sulfamethoxazole | 60% | – | – | – |
| Vancomycin | 0% | – | – | – |
| Clindamycin | 73% | – | – | – |
| Azithromycin | 80% | – | – | – |
| Levofloxacin | 80% | 100% | 83.3% | 71.4% |
| Colistin | – | 0% | 0% | 0% |
| Cefepime | – | 38.1% | 66.7% | 35.7% |
| Ceftriaxone | – | 100% | 66.7% | 78.6% |
| Meropenem | – | 95.2% | 33.3% | 64.3% |
| Cefotaxime | – | 100% | 66.7% | 85.7% |
| Piperacillin + Tazobactam | 100% | 33.3% | 64.3% |
Typing of Gram-negative bacteria based on rep- PCR typing method from patients with HAP
| Bacterial isolated | A | B | C | D | E | F | G |
|---|---|---|---|---|---|---|---|
| 1, 2, 124, 14, 19 | 4, 6, 8, 9, 13, 15 | 3, 10, 17 | 5, 11 | 16, 18 | 7 | 12 | |
| 2, 5, 11 | 3, 6 | 4, 9 | 7 | 8 | 10 | – | |
| 1, 2 | 3, 5 | 4 | 7 | – | – | – |
Fig. 1Molecular typing of Gram-negative isolates using rep-PCR method. A Showed different patterns in A. baumannii, B showed different patterns in P. aeruginosa